Journal of the National Comprehensive Cancer Network-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2025-05-02 科研一萌新来自安徽省

偏重的研究方向：白血病
经验分享：2025-04-26 Received/Under Preliminary Consideration；
2025-04-29 Under Consideration
2025-04-30 Under Review
焦急等待中，不确定是否外审

15 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-08-28 总是有一手来自安徽省

Received/Under Preliminary Consideration 13天了不知道啥情况了

132 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2025-05-02 科研一萌新来自安徽省

偏重的研究方向：白血病
经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中

10 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2024-10-26 120aa17dm05暂无昵称来自上海

我没有

32 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2024-02-03 ms3000001535095984 来自北京

1

123 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-08-15 Mr.HHe 来自江西省

偏重的研究方向：队列研究;临床肿瘤研究
经验分享：历时4个月录取了

95 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-08-15 Mr.HHe 来自江西省

3.31 投稿
6.08 一修回来
6.25 第一次修改返回去
8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片
8.15 凌晨5点文章接受

111 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-03-03 瓜瓜guagua

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：临床肿瘤研究;队列研究
经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！

206 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-11-24 qj756412748 来自浙江省

偏重的研究方向：胃癌
经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中

115 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263136, encodeId=1f4f2263136fc, content=偏重的研究方向：白血病 经验分享：2025-04-26 Received/Under Preliminary Consideration； 2025-04-29 Under Consideration 2025-04-30 Under Review 焦急等待中，不确定是否外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:10:31 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2263137, encodeId=d9a2226313ef7, content=偏重的研究方向：白血病 经验分享：2025-04-26 投稿 04-29 Under consideration 04-30 Under review 焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=科研一萌新, createdTime=Fri May 02 06:19:43 CST 2025, time=2025-05-02, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2233224, encodeId=82c322332241c, content=我没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d55d2197958, createdName=120aa17dm05暂无昵称, createdTime=Sat Oct 26 09:19:54 CST 2024, time=2024-10-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

什么是Protocol？

147 1 举报

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务